The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
Indices for predicting HBsAg or HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection during antiviral therapy remain elusive. We aimed to investigate if the presence of HBsAb-specific B cells at baseline can predict HBsAg or HBeAg seroconversion. In this study, 134 treatme...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2259003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423346744164352 |
|---|---|
| author | Shengxia Yin Yawen Wan Rahma Issa Yijia Zhu Xiaoming Xu Jiacheng Liu Minxin Mao Ming Li Xin Tong Chen Tian Jian Wang Rui Huang Qun Zhang Chao Wu Yuxin Chen Jie Li |
| author_facet | Shengxia Yin Yawen Wan Rahma Issa Yijia Zhu Xiaoming Xu Jiacheng Liu Minxin Mao Ming Li Xin Tong Chen Tian Jian Wang Rui Huang Qun Zhang Chao Wu Yuxin Chen Jie Li |
| author_sort | Shengxia Yin |
| collection | DOAJ |
| description | Indices for predicting HBsAg or HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection during antiviral therapy remain elusive. We aimed to investigate if the presence of HBsAb-specific B cells at baseline can predict HBsAg or HBeAg seroconversion. In this study, 134 treatment-naive patients with chronic HBV were enrolled. A baseline HBsAb-specific B cell ELISpot assay was performed for all the patients that enrolled. Serum samples were collected at 12, 24, and 48 weeks for patients treated with Peg-IFN-α, or at 1 year, 3 years, and 5 years for patients treated with NAs. Laboratory testing of HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV DNA, ALT, and AST was done. We observed a significantly lower frequency of HBsAb-specific B cells in patients with chronic HBV than in healthy individuals . In the Peg-IFN-α-treated group, 41.2% of patients with baseline HBsAb-specific B cells achieved HBsAg seroconversion, while only 13.6% of patients without baseline HBsAb-specific B cells achieved HBsAg seroconversion (p = 0.006). By logistic regression analysis, patients with baseline HBsAb-specific B cells and HBsAg ≤ 1500 had higher HBsAg clearance at the end of treatment (p < 0.05). In the NA-treated group, 58.3% of patients with baseline HBsAb-specific B cells achieved HBeAg seroconversion, whereas only 30.0% of patients without baseline HBsAb-specific B cells achieved HBeAg seroconversion (p = 0.114). Our result revealed that baseline HBsAb-specific B cells by ELISpot assay might be a valuable predictive biomarker of HBsAg or HBeAg seroconversion in patients with chronic HBV on treatment. |
| format | Article |
| id | doaj-art-c8af4198e7ea45f6858f1002c9e3681b |
| institution | Kabale University |
| issn | 2222-1751 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-c8af4198e7ea45f6858f1002c9e3681b2025-08-20T03:30:37ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112210.1080/22221751.2023.2259003The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatmentShengxia Yin0Yawen Wan1Rahma Issa2Yijia Zhu3Xiaoming Xu4Jiacheng Liu5Minxin Mao6Ming Li7Xin Tong8Chen Tian9Jian Wang10Rui Huang11Qun Zhang12Chao Wu13Yuxin Chen14Jie Li15Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Affiliated Zhongda Hospital of Southeast University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Affiliated Zhongda Hospital of Southeast University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People’s Republic of ChinaIndices for predicting HBsAg or HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection during antiviral therapy remain elusive. We aimed to investigate if the presence of HBsAb-specific B cells at baseline can predict HBsAg or HBeAg seroconversion. In this study, 134 treatment-naive patients with chronic HBV were enrolled. A baseline HBsAb-specific B cell ELISpot assay was performed for all the patients that enrolled. Serum samples were collected at 12, 24, and 48 weeks for patients treated with Peg-IFN-α, or at 1 year, 3 years, and 5 years for patients treated with NAs. Laboratory testing of HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV DNA, ALT, and AST was done. We observed a significantly lower frequency of HBsAb-specific B cells in patients with chronic HBV than in healthy individuals . In the Peg-IFN-α-treated group, 41.2% of patients with baseline HBsAb-specific B cells achieved HBsAg seroconversion, while only 13.6% of patients without baseline HBsAb-specific B cells achieved HBsAg seroconversion (p = 0.006). By logistic regression analysis, patients with baseline HBsAb-specific B cells and HBsAg ≤ 1500 had higher HBsAg clearance at the end of treatment (p < 0.05). In the NA-treated group, 58.3% of patients with baseline HBsAb-specific B cells achieved HBeAg seroconversion, whereas only 30.0% of patients without baseline HBsAb-specific B cells achieved HBeAg seroconversion (p = 0.114). Our result revealed that baseline HBsAb-specific B cells by ELISpot assay might be a valuable predictive biomarker of HBsAg or HBeAg seroconversion in patients with chronic HBV on treatment.https://www.tandfonline.com/doi/10.1080/22221751.2023.2259003HBsAbChronic HBVHBsAg seroconversionPeg-IFN-α treatmentELIspotHBsAb-specific B cells |
| spellingShingle | Shengxia Yin Yawen Wan Rahma Issa Yijia Zhu Xiaoming Xu Jiacheng Liu Minxin Mao Ming Li Xin Tong Chen Tian Jian Wang Rui Huang Qun Zhang Chao Wu Yuxin Chen Jie Li The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment Emerging Microbes and Infections HBsAb Chronic HBV HBsAg seroconversion Peg-IFN-α treatment ELIspot HBsAb-specific B cells |
| title | The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment |
| title_full | The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment |
| title_fullStr | The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment |
| title_full_unstemmed | The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment |
| title_short | The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment |
| title_sort | presence of baseline hbsab specific b cells can predict hbsag or hbeag seroconversion of chronic hepatitis b on treatment |
| topic | HBsAb Chronic HBV HBsAg seroconversion Peg-IFN-α treatment ELIspot HBsAb-specific B cells |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2023.2259003 |
| work_keys_str_mv | AT shengxiayin thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yawenwan thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT rahmaissa thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yijiazhu thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT xiaomingxu thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jiachengliu thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT minxinmao thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT mingli thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT xintong thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT chentian thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jianwang thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT ruihuang thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT qunzhang thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT chaowu thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yuxinchen thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jieli thepresenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT shengxiayin presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yawenwan presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT rahmaissa presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yijiazhu presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT xiaomingxu presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jiachengliu presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT minxinmao presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT mingli presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT xintong presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT chentian presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jianwang presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT ruihuang presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT qunzhang presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT chaowu presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT yuxinchen presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment AT jieli presenceofbaselinehbsabspecificbcellscanpredicthbsagorhbeagseroconversionofchronichepatitisbontreatment |